Evaluation of quality of life using ASQoL questionnaire in patients with ankylosing spondylitis in a Chinese population.
The purpose of this study was to evaluate the reliability of Chinese version of the ankylosing spondylitis quality of life questionnaire (ASQoL) for AS patients. All the enrolled AS patients should fulfill five questionnaires (BASDAI, BASFI, DFI, BAS-G and ASQoL) by himself, then the investigators did physical examination of the patients, fulfilling BASMI. Physical function has a strong correlation with QoL in patients with AS. In different disease activity groups, ASQoL had a correlation with BASFI, especially in the moderate activity group (gamma = 0.66, P < 0.0001). All four questionnaires in entanacept treatment group improved distinctly on week 6 and 12 comparing to baseline. There were significantly correlations of changing between ASQoL and BAS-G, BASDAI and BASFI after treatment with etanercept in AS patients. The Chinese ASQoL questionnaire is valuable to evaluate the activity of AS patients and effect of biologic agent treatment in patients with AS. It is a good generic instrument to measure QoL in patients with AS in China.
Zhao
L K
LK
Division of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Road, Guangzhou 510630, People's Republic of China.
Liao
Z T
ZT
Li
C H
CH
Li
T W
TW
Wu
J
J
Lin
Q
Q
Huang
F
F
Yu
D T
DT
Gu
J R
JR
D000203:Activities of Daily Living; D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D044466:Asian People; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D009043:Motor Activity; D010919:Placebos; D011788:Quality of Life; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D015203:Reproducibility of Results; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology*; D011795:Surveys and Questionnaires / Q000592:standards*
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D010919:Placebos; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept